查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566982

病毒載體和質體DNA 製造市場：按載體類型、工作流程、應用和最終用戶：2024-2033 年全球機會分析和產業預測

Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus , Lentivirus, Plasmids, Others), By Workflow By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

病毒載體及質體DNA製造市場

2023年病毒載體及質體DNA製造市值為53億美元，預估2024年至2033年複合年成長率為20.4%，至2033年達340億美元。

病毒載體和質體DNA 是基因工程的重要組成部分，可用於多種目的，包括基因治療和疫苗生產。病毒載體是一種分子載體，用於透過基因表現或將遺傳物質整合到細胞 DNA 中將遺傳訊息轉移到細胞中。質體DNA 是細菌中發現的染色體外環狀 DNA。用作基因克隆和基因治療的載體。病毒載體和質體DNA 可以使用多種方法生產，包括細胞培養系統、精製過程和細菌發酵。

遺傳疾病的日益普及和技術進步正在促進基因治療的實施，從而推動病毒載體和質體DNA 製造市場的成長。此外，由於政府和食品藥物管理局等監管機構的投資激增和支持，研發活動的增加正在推動對病毒載體和質體DNA 製造的需求。使用人工智慧和機器學習演算法來提高製造的可擴展性的趨勢日益明顯。演算法有助於確定精確的要求和理想條件，以最大限度地提高載體和質體的產量。

然而，在製造過程中防止污染是一個挑戰，因為一個小異物可能會毀掉整個生產批次。這項挑戰極大地限制了病毒載體和質體DNA 製造市場的成長。此外，製造所需設備的採購和維護成本非常昂貴，限制了小型企業和研究機構的投資並阻礙了市場成長。此外，世界各地監管程序的差異限制了載體和質體在某些地區的效用。例如，歐洲指南要求在製造的各個階段遵守當前的良好製造規範。相較之下，美國食品藥物管理局(FDA) 允許某些材料和所有相關屬性或驗收標準在產品開發的第一階段保持未知。

分部審查

病毒載體和質體DNA 製造市場分為載體類型、工作流程、應用、最終用戶和區域。依載體類型分為腺病毒、逆轉錄病毒、腺結合病毒（AAV）、慢病毒、質體等。工作流程分為上游製造和下游製造。依用途分為反義&RNAi療法、反義&RNAi療法、細胞療法、疫苗療法和研究用途。依最終用戶分為製藥/生物製藥公司和研究機構。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按載體類型分類，腺結合病毒(AAV) 細分市場在 2023 年佔據主導地位。

從工作流程來看，下游製造領域在2023年佔據了較高的市場佔有率。

從應用來看，2023年疫苗接種領域在市場中佔有較高佔有率。

按最終用戶分類，研究機構細分市場將在 2023 年獲得較高佔有率。

按地區分類，北美地區 2023 年收益最高。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章病毒載體與質體DNA 製造市場：依載體型

  • 市場概況
  • 腺病毒
  • 逆轉錄病毒
  • 腺相關病毒（AAV）
  • 慢病毒
  • 質體
  • 其他

第5章病毒載體與質體DNA 製造市場：依工作流程

  • 市場概況
  • 上游製造
  • 下游製造

第6章病毒載體與質體DNA 製造市場：依應用分類

  • 市場概況
  • 反義RNAi療法
  • 反義RNAi療法
  • 細胞療法
  • 疫苗治療
  • 研究用途

第7章 病毒載體與質體DNA 製造市場：依最終使用者分類

  • 市場概況
  • 醫藥生物製藥公司
  • 研究所

第8章病毒載體和質體DNA 製造市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國病毒載體及質體DNA製造市場
    • 加拿大病毒載體與質體DNA製造市場
    • 墨西哥病毒載體與質體DNA製造市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國病毒載體與質體DNA製造市場
    • 法國病毒載體與質體DNA製造市場
    • 英國病毒載體與質體DNA製造市場
    • 義大利病毒載體及質體DNA製造市場
    • 西班牙病毒載體與質體DNA製造市場
    • 其他歐洲病毒載體及質體DNA 製造市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本病毒載體及質體DNA製造市場
    • 中國病毒載體與質體DNA製造市場
    • 澳洲病毒載體及質體DNA製造市場
    • 印度的病毒載體與質體DNA製造市場
    • 韓國病毒載體及質體DNA製造市場
    • 其他亞太病毒載體及質體DNA 製造市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西病毒載體及質體DNA製造市場
    • 沙烏地阿拉伯的病毒載體和質體DNA製造市場
    • 南非的病毒載體與質體DNA製造市場
    • 其他拉丁美洲/中東/非洲病毒載體和質體DNA 製造市場

第9章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第10章 公司簡介

  • Merck KGaA
  • Lonza Group AG
  • FUJIFILM Corporation
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent Inc.
  • WuXi Biologics.
  • TakarBio Inc
  • Waisman Biomanufacturing, LLC
  • Genezen Laboratories
簡介目錄
Product Code: A324540

Viral Vectors and Plasmid DNA Manufacturing Market

The viral vectors and plasmid DNA manufacturing market was valued at $5.3 billion in 2023 and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.

Viral vector and plasmid DNA are the crucial components of genetic engineering, utilized for diverse purposes such as gene therapy and vaccine production. A viral vector is a form of molecular vehicle used to transfer genetic information to the cells either through gene expression or integration of genetic material into the cell's DNA. Plasmid DNA is an extrachromosomal circular piece of DNA present in bacteria. It serves as a vector for gene cloning, and gene therapy. The manufacturing of viral vectors and plasmid DNA is accomplished through various methods such as cell culture systems, purification processes, or bacterial fermentation.

Increase in the prevalence of genetic disorders and advancements in technology have facilitated the execution of gene therapies, thereby driving the growth of the viral vectors and plasmid DNA manufacturing market. In addition, rise in R&D activities due to surge in investments & support from government and regulatory agencies such as the Food and Drug administration is boosting the demand for the manufacturing for viral vectors and plasmid DNA. To enhance the scalability of production, the trend of using AI and ML algorithms is gaining prominence. The algorithm helps in identifying the precise requirements and ideal conditions to maximize the production of vectors and plasmid.

However, preventing contamination during manufacturing is challenging as a tiny foreign particle is capable of spoiling the entire production batch. This challenge significantly restrains the growth of the viral vectors and plasmid DNA manufacturing market. In addition, the procurement and maintenance of the equipment required for production is highly expensive, which limits several small-scale firms and laboratories from investing, hence hampering the market growth. Moreover, discrepancies in the regulatory process across the globe restrict the utility of the vectors and plasmid in certain regions. For instance, the European guidelines have mandated the compliance of products with the current good manufacturing practices standards at all stages of production. Contrarily, as per the U.S. Food and Drug Administration, it is acceptable that some materials and all relevant attributes or acceptance criteria remain unknown at stage 1 of product development.

Segment Review

The viral vectors and plasmid DNA manufacturing market is segmented into vector type, workflow, application, end user, and region. On the basis of vector type, the market is divided into adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Depending on workflow, it is bifurcated into upstream manufacturing and downstream manufacturing. As per application, it is classified into antisense & RNAi therapy, antisense & RNAi therapy, cell therapy, vaccinology, and research applications. According to end user, it is categorized into pharmaceutical & biopharmaceutical companies and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of vector type, the adeno-associated virus (AAV) segment dominated the market in 2023.

Depending on workflow, the downstream manufacturing segment accounted for a high market share in 2023.

As per application, the vaccinology segment acquired a high stake in the market in 2023.

According to end user, the research institutes segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global viral vectors and plasmid DNA manufacturing market include Merck KGaA, Lonza Group AG, FUJIFILM Corporation, thermo fisher scientific, Cobra Biologics, Catalent Inc., WuXi Biologics., TakarBio Inc, Waisman Biomanufacturing, LLC, and Genezen laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

By Workflow

  • Upstream Manufacturing
  • Downstream Manufacturing

By Application

  • Antisense RNAi Therapy
  • Antisense RNAi Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

By End User

  • Pharmaceutical Biopharmaceutical Companies
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Merck KGaA
    • Lonza Group AG
    • FUJIFILM Corporation
    • Thermo Fisher Scientific Inc.
    • Cobra Biologics
    • Catalent Inc.
    • WuXi Biologics.
    • TakarBio Inc
    • Waisman Biomanufacturing, LLC
    • Genezen laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Vector Type
  • 4.2. Adenovirus
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Retrovirus
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Adeno-Associated Virus (AAV)
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Lentivirus
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Plasmids
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Others
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country

CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Workflow
  • 5.2. Upstream Manufacturing
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Downstream Manufacturing
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Application
  • 6.2. Antisense RNAi Therapy
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Antisense RNAi Therapy
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Cell Therapy
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Vaccinology
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country
  • 6.6. Research Applications
    • 6.6.1. Key Market Trends, Growth Factors and Opportunities
    • 6.6.2. Market Size and Forecast, By Region
    • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By End User
  • 7.2. Pharmaceutical Biopharmaceutical Companies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Research Institutes
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country

CHAPTER 8: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Vector Type
    • 8.2.3. Market Size and Forecast, By Workflow
    • 8.2.4. Market Size and Forecast, By Application
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.7.1. Market Size and Forecast, By Vector Type
      • 8.2.7.2. Market Size and Forecast, By Workflow
      • 8.2.7.3. Market Size and Forecast, By Application
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.8.1. Market Size and Forecast, By Vector Type
      • 8.2.8.2. Market Size and Forecast, By Workflow
      • 8.2.8.3. Market Size and Forecast, By Application
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.2.9.1. Market Size and Forecast, By Vector Type
      • 8.2.9.2. Market Size and Forecast, By Workflow
      • 8.2.9.3. Market Size and Forecast, By Application
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Vector Type
    • 8.3.3. Market Size and Forecast, By Workflow
    • 8.3.4. Market Size and Forecast, By Application
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.7.1. Market Size and Forecast, By Vector Type
      • 8.3.7.2. Market Size and Forecast, By Workflow
      • 8.3.7.3. Market Size and Forecast, By Application
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.8.1. Market Size and Forecast, By Vector Type
      • 8.3.8.2. Market Size and Forecast, By Workflow
      • 8.3.8.3. Market Size and Forecast, By Application
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. UK Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.9.1. Market Size and Forecast, By Vector Type
      • 8.3.9.2. Market Size and Forecast, By Workflow
      • 8.3.9.3. Market Size and Forecast, By Application
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.10.1. Market Size and Forecast, By Vector Type
      • 8.3.10.2. Market Size and Forecast, By Workflow
      • 8.3.10.3. Market Size and Forecast, By Application
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.11.1. Market Size and Forecast, By Vector Type
      • 8.3.11.2. Market Size and Forecast, By Workflow
      • 8.3.11.3. Market Size and Forecast, By Application
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.3.12.1. Market Size and Forecast, By Vector Type
      • 8.3.12.2. Market Size and Forecast, By Workflow
      • 8.3.12.3. Market Size and Forecast, By Application
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Vector Type
    • 8.4.3. Market Size and Forecast, By Workflow
    • 8.4.4. Market Size and Forecast, By Application
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.7.1. Market Size and Forecast, By Vector Type
      • 8.4.7.2. Market Size and Forecast, By Workflow
      • 8.4.7.3. Market Size and Forecast, By Application
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.8.1. Market Size and Forecast, By Vector Type
      • 8.4.8.2. Market Size and Forecast, By Workflow
      • 8.4.8.3. Market Size and Forecast, By Application
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.9.1. Market Size and Forecast, By Vector Type
      • 8.4.9.2. Market Size and Forecast, By Workflow
      • 8.4.9.3. Market Size and Forecast, By Application
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.10.1. Market Size and Forecast, By Vector Type
      • 8.4.10.2. Market Size and Forecast, By Workflow
      • 8.4.10.3. Market Size and Forecast, By Application
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.11.1. Market Size and Forecast, By Vector Type
      • 8.4.11.2. Market Size and Forecast, By Workflow
      • 8.4.11.3. Market Size and Forecast, By Application
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.4.12.1. Market Size and Forecast, By Vector Type
      • 8.4.12.2. Market Size and Forecast, By Workflow
      • 8.4.12.3. Market Size and Forecast, By Application
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Vector Type
    • 8.5.3. Market Size and Forecast, By Workflow
    • 8.5.4. Market Size and Forecast, By Application
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.7.1. Market Size and Forecast, By Vector Type
      • 8.5.7.2. Market Size and Forecast, By Workflow
      • 8.5.7.3. Market Size and Forecast, By Application
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.8.1. Market Size and Forecast, By Vector Type
      • 8.5.8.2. Market Size and Forecast, By Workflow
      • 8.5.8.3. Market Size and Forecast, By Application
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. South Africa Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.9.1. Market Size and Forecast, By Vector Type
      • 8.5.9.2. Market Size and Forecast, By Workflow
      • 8.5.9.3. Market Size and Forecast, By Application
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Viral Vectors and Plasmid DNA Manufacturing Market
      • 8.5.10.1. Market Size and Forecast, By Vector Type
      • 8.5.10.2. Market Size and Forecast, By Workflow
      • 8.5.10.3. Market Size and Forecast, By Application
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Merck KGaA
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Lonza Group AG
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. FUJIFILM Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Thermo Fisher Scientific
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Cobra Biologics
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Catalent Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. WuXi Biologics.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. TakarBio Inc
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Waisman Biomanufacturing, LLC
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Genezen Laboratories
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments